With SCEMBLIX® (asciminib), more patients achieved deep MR vs bosutinib at Week 24 through to Week 1562,8

No statistical analysis was available at the time of publication

MR4 at Week 242,8

Image
MR4 at Week 24
Image
MR4 at Week 96

MR4 at Week 968